Abstract 1194P
Background
Artificial intelligence (AI) based on deep learning and convolutional neural networks (CNN) has been applied to various medical fields. We are developing a novel AI system to support the detection of lung cancer, which will enable physicians to efficiently interpret radiograms and perform diagnosis.
Methods
For training data, we analyzed the image features of 800 chest X-ray images (acquired mainly for lung cancer screening; 400 normal images and 400 abnormal images) from Fukushima Preservative Service Association of Health and 5 000 chest radiographs from the National Institutes of Health (NIH) database. We categorized these data into two groups. Group A included both 800 images and NIH database, and group B included only 800 images. Then, using ImageNet, we used these datasets to develop a proprietary AI algorithm with deep learning and a CNN, and analyzed the statistical accuracy of interpretations of the radiograms. We also demonstrated abnormal shadow in the form of a heat map display on each chest radiograph for easy visualization, and presented the positive probability score as an index value from 0.0 to 1.0 indicating the possibility of lung cancer. The accuracy of our AI system was improved by using technology to account for differences in radiographic apparatus and imaging environments.
Results
Using a positive probability cutoff value of 0.5, our novel AI showed an area under the curve (AUC) of 0.74, sensitivity of 0.75, and specificity of 0.60 for group A, and AUC of 0.79, sensitivity of 0.72, and specificity of 0.74 for group B. The accuracy on both groups was superior to that of radiologists (AUC 0.72), and was also compatible with previous study reports (AUC 0.67-0.78). The number of training data did not make a difference in accuracy. The heat map display was also clearly demonstrated on the monitor screen if a roentgenogram had abnormal shadows.
Conclusions
In this study, we confirmed that our proprietary AI system had a similar accuracy in the interpretation of chest radiographs to that of previous studies and radiologists. However, further research and improvement is needed to verify the accuracy. We are now in the process of performing various types of validation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Grants-in-Aid for Scientific Research in Japan.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
707P - Paclitaxel, ifosfamide and cisplatin (TIP) in patients (pts) with poor prognosis nonseminomatous germ cell tumor (NSGCT) with unfavourable serum tumor markers (STM) decline: A phase II study
Presenter: Edgar Israelyan
Session: Poster session 09
708P - The Empower Pathway: An audit of the first 150 patients. Enhanced personalised care of testicular cancer survivors
Presenter: Penny Champion
Session: Poster session 09
817P - A machine learning algorithm utilizing clinicopathologic parameters for extranodal natural killer/T cell lymphoma
Presenter: Shuo Li
Session: Poster session 09
Resources:
Abstract
818P - The association between hospital volume and overall survival in adult AML patients treated with intensive chemotherapy
Presenter: Z.L.Rana Kaplan
Session: Poster session 09
819P - Efficacy and safety of orelabrutinib plus R-CHOP-like regimens for treatment-naïve diffuse large B-cell lymphoma with double expression
Presenter: Wei Wan
Session: Poster session 09
820P - Second primary malignancies and disease transformation in symptomatic patients with Waldenstrom’s macroglobulinemia: Outcomes of a population-based analysis
Presenter: Vasiliki Spiliopoulou
Session: Poster session 09
821P - Circulating chromosomal alterations in lymphoid malignancies
Presenter: Rosalie Griffin
Session: Poster session 09
822P - Preliminary results from a phase Ib study of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma
Presenter: Lijuan Deng
Session: Poster session 09
823P - The bone marrow immune ecosystem shapes acquired resistance to daratumumab in plasma cell myeloma
Presenter: Yun Wang
Session: Poster session 09
824P - FLT3-ITD induces immune escape in AML via up-regulating CD47 expression and decreased phagpcytic ability of macrophages
Presenter: Shuzhao Chen
Session: Poster session 09